In the literature, several adult cases with myelin oligodendrocyte glycoprotein (MOG) antibodies (Abs)-associated disorders have been reported to have seizure and acute disseminated encephalomyelitis (ADEM) as the main clinical manifestations, but the number is somewhat low. Because of its rarity, the clinical characteristics and a consensus on treatment have not yet been established in the adult form of ADEM and seizure phenotypes in MOG-Abs-associated disorders. In this report, we described an adult patient who presented with status epilepticus as the index event, had been suffering from chronic epilepsy, and had positive antibodies for MOG. Neither increasing the doses of the antiseizure drugs (ASDs) nor adding another new ASD reduced the prevalence of the seizures. However, he became seizure-free after the addition of azathioprine and incremental increases of methylprednisolone dosage. This case clearly indicates the effectiveness of corticosteroid and azathioprine, as well as the futility of ASDs in the management of seizure control by showing the temporal trajectory relationship among ASDs, steroids, azathioprine and seizure frequency.

Keywords: Myelin-oligodendrocyte glycoprotein, Epilepsy, Immunosuppressive agents

Case Report
A 49-year-old male presented to the emergency department (ED) with first-ever seizure. He had no past medical history. In the ED, his body temperature was 37.9°C, and he manifested recurrent generalized tonic seizures without recovering baseline cognitive function between seizures. An intravenous (IV) dose of lorazepam followed by IV fosphenytoin and levetiracetam (LEV) failed to control recurrent convulsive seizures. The convulsive SE lasted for approximately 12 hours, and the patient's convulsive seizures finally subsided with thiopental therapy. A cerebrospinal fluid study was normal. IV acyclovir, methylprednisolone, and immunoglobulin were administered and maintained. After administration of IV methylprednisolone for 5
days, oral methylprednisolone was initiated and maintained at a dosage of 70 mg/day. Electroencephalogram (EEG) showed frequent spike and wave discharges arising from the left temporo-occipital lobe.

Magnetic resonance imaging (MRI) with gadolinium enhancement of the brain demonstrated bilateral, asymmetric, multifocal, and hyperintense lesions involving mainly the juxtacortical subcortices and the bilateral insula without contrast enhancement or diffusion restriction (Figure 1A–C). The hyperintense centers of the lesions were surrounded by slightly less hyperintense areas with fuzzy margins (arrows in Figure 1).

An antibody study against MOG-Abs using cell-based assays with flow cytometry (CBA-FACS) yielded a positive test result, with an MOG-expressing cell binding ratio (MBR) of 12.29% (reference, positive of > 9.94%). Other laboratory studies were conducted to diagnose connective tissue diseases, vasculitis, and any other systemic diseases, including tests for identification of antithyroid peroxidase Ab; thyrotropin receptor Ab; thyroglobulin Ab; lupus anticoagulant; antineutrophil cytoplasmic Ab; anti SS-related antigen B (anti La); human leukocyte antigens (HLA) B27, HLA B51, C3, and C4; double-stranded DNA Ab; antinuclear Ab; and CBA-FACS anti-aquaporin 4 Ab. These tests were all unremarkable. One month after admission to the hospital, the patient’s mental status was fully recovered without any neurological sequelae. The patient was discharged from the hospital with maintenance medications of 300 mg/day of valproate (VPR) and 1,000 mg/day of LEV. After the patient was discharged from the hospital, methylprednisolone was gradually tapered over a period of 40 days and then discontinued, without seizure recurrence. The abnormal lesions previously detected on MRI were resolved in the follow-up brain MRI, suggesting demyelinating pathology rather than axonal injury (Figure 1D–F). However, MOG-Ab remained in the follow-up test (MBR, 10.55%).

Thirty-six days after methylprednisolone was discontinued, the patient experienced a focal impaired awareness tonic seizure evolving to a bilateral tonic-clonic seizure. EEG revealed interictal spike and wave discharges from the left temporo-occipital lobe. The clinical and treatment courses regarding seizure frequency, antiseizure drugs (ASDs), and immunosuppressant

Figure 1 The brain MRI images of initial and 5-month follow-up

(A–C) Initial MRI with gadolinium enhancement of the patient’s brain. It demonstrates bilateral, asymmetric, multifocal, and hyperintense lesions involving the juxtacortical subcortices and the insula cortices without contrast enhancement or diffusion restriction. The hyperintense centers of the lesions are surrounded by slightly less hyperintense areas with fuzzy margins (arrows). (D–F) Follow-up MRI of 5 months later. The lesions had resolved.

MRI, magnetic resonance imaging.
agents are depicted in Figure 2. The dosages of ASDs before recurrence of seizure were 300 mg/day of VPR and 1,000 mg/day of LEV; after seizure recurrence, those were escalated to 1,500 mg/day of VPR and 2,000 mg/day of LEV, with newly added-on oxcarbazepine 900 mg/day.

The ASDs were not effective, and the frequency of seizures increased. The patient’s drug-refractory epilepsy was eventually managed, and a seizure-free state was achieved by addition of azathioprine accompanied by titration of methylprednisolone from 5 to 10 mg/day. After effective response to immunotherapy, the doses of VPR and LEV were reduced to 300 and 500 mg/day, respectively.

**Discussion**

Analysis of the 23 most recently published studies in which the clinical and MRI characteristics of patients with MOG-Abs were evaluated clearly indicates age-dependent clinical features [1]. Young children most often present with ADEM with an opticospinal manifestation, though ADEM is very rare in adults [1]. None of the 26 adult patients with MOG-Abs in a case series manifested ADEM features on MRI [3]. In contrast, our patient showed multiple juxtacortical and cortical reversible brain lesions with blurred margins, compatible with the characteristic features of ADEM.

In 2017, an adult with focal and secondarily generalized seizures was reported and shown to be positive for MOG-Abs [2]. In that case, a relapse of optic neuritis occurred when methylprednisolone was tapered. Chronic epilepsy is very rare in MOG encephalitis. A retrospective study evaluating 61 MOG encephalomyelitis patients reported 13 patients (21.3%) with epileptic seizures, most of which were single, while SE was very rare (4%). Among the 13 patients with epileptic seizures, only two (15.4%) developed chronic epilepsy [4].

Although there is no established treatment consensus regarding the management of seizures in patients with MOG, a few studies reported that the seizures were responsive to steroids and/or immunosuppressants [1,2]. The present study provides evidence that patients with MOG-Abs and seizures are responsive to immunosuppressants and steroids based on a temporal relationship between ASDs, steroids, azathioprine, and seizure frequency. It has been reported that a subset of patients with medically intractable epilepsy have autoimmune epilepsy, and immunotherapy was very effective in these patients [5]. A trial of immunotherapy should be considered in patients with suspect-
ed autoimmune epilepsy.

In conclusion, we reported an adult patient who carried antibodies against MOG, presented with SE as the index event, and developed chronic epilepsy. The patient manifested ADEM-like features on MRI. Not sufficiently managed by ASDs, the chronic epilepsy was controlled by an immunosuppressant agent with a corticosteroid. Clinicians should use immunosuppressant agents as a first-line therapy for management of epilepsy in MOG-Ab-associated disorders.

**Conflicts of Interest**

No potential conflict of interest relevant to this article was reported.

**Author Contributions**

Conceptualization, Data curation, Formal analysis, Project administration, Resources, Supervision, Validation: T Kim; Investigation: all authors; Writing–original draft: all authors; Writing–review & editing: all authors.

**References**

1. Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 2019;15:89–102.
2. Fujimori J, Takai Y, Nakashima I, et al. Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. J Neurol Neurosurg Psychiatry 2017;88:534–536.
3. Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 2018;89:127–137.
4. Yao Y, Xu Y, Ren H, et al. Acute epileptic seizures in myelin oligodendrocyte glycoprotein encephalomyelitis and neuromyelitis optica spectrum disorder: a comparative cohort study. Mult Scler Relat Disord 2019;27:281–288.
5. Toledano M, Britton JW, McKeon A, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 2014;82:1578–1586.